Allergan Inc (AGN)

AGN (NYSE:Drugs)
$166.71
pos +1.06
+0.64%
Today's Range: 163.02 - 166.85 | AGN Avg Daily Volume: 3,542,400
Last Update: 04/24/14 - 2:41 PM EDT
Volume: 4,741,153
YTD Performance: 49.13%
Open: $164.26
Previous Close: $165.65
52 Week Range: $81.33 - $166.00
Oustanding Shares: 298,467,649
Market Cap: 48,949,185,232
6-Month Chart
TheStreet Ratings Grade for AGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 9 10 11
Moderate Buy 0 0 0 0
Hold 5 7 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
Mean Rec. 1.88 1.88 1.89 1.84
Latest Dividend: 0.05
Latest Dividend Yield: 0.15%
Dividend Ex-Date: 02/26/14
Price Earnings Ratio: 31.24
Price Earnings Comparisons:
AGN Sector Avg. S&P 500
31.24 50.50 29.23
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
42.36% 45.19% 112.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.50 0.28 0.09
Net Income -10.30 258.69 5.26
EPS -9.80 0.00 0.00
Earnings for AGN:
EBITDA 2.07B
Revenue 6.30B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.12 $1.35 $5.45 $6.22
Number of Analysts 12 12 15 13
High Estimate $1.13 $1.41 $5.50 $6.30
Low Estimate $1.09 $1.24 $5.38 $6.08
Prior Year $0.98 $1.22 $4.77 $5.45
Growth Rate (Year over Year) 13.86% 10.59% 14.34% 13.96%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Doug Kass

 | Apr 23, 2014 | 2:00 PM EDT
Run, don't walk, to watch Ackman and Pearson on Bloomberg TV.
By

Jim Cramer

 | Apr 23, 2014 | 1:38 PM EDT

Let's tick down what hasn't gone wrong -- and what's making this market so resilient.

By

Sham Gad

 | Apr 23, 2014 | 1:00 PM EDT

During bull markets, it's even more important to avoid portfolio damage.

By

Doug Kass

 | Apr 23, 2014 | 9:27 AM EDT
 No wonder the average investor feels disenfranchised.

bullishAllergan upgraded at JP Morgan

Apr 23, 2014 | 7:58 AM EDT

AGN was upgraded to from Neutral to Overweight, JP Morgan said. $190 price target. See value in a potential transaction with Valeant. 

By

Jim Cramer

 | Apr 22, 2014 | 1:48 PM EDT

The deck seems stacked against this pharmaceutical powerhouse.

By

Jim Cramer

 | Apr 22, 2014 | 11:27 AM EDT

Internet and biotech stocks are trading as a cohort right now.

By

Paul Curcio

 | Apr 22, 2014 | 9:00 AM EDT

Futures point higher; blockbuster drug deal boosts European markets.

bullishAllergen price target, EPS lifted at Jefferies

Apr 22, 2014 | 8:02 AM EDT

AGN raised its numbers, Jefferies said. Double digit growth with productive R&D and superior execution. $139 price target and Hold rating. 

By

Jim Cramer

 | Apr 17, 2014 | 1:12 PM EDT

Some unexpected stocks and sectors have climbed the market's wall of worry.

The wicked, whipsaw action following FB's earnings release last evening warns me the stock...
This stock has been a dog for years, but its ears are perking here lately, and today has m...
Good afternoon! Oil has taken a swift turn this week and is showing further weakness ahead...

I'm looking for buy triggers in TSLA on this pullback. The last low is key!

...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.